Triple-agent regimen improves survival
BOTHELL, Wash.—Seattle Genetics Inc. recently shared top-line results from its HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine vs. trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer. The combination of the three drugs reduced the risk of disease progression or death by 46 percent, meeting the primary endpoint of progression-free survival, as well as improving overall survival by 34 percent. In the tucatinib arm, patients whose cancer had metastasized to the brain saw a 52-percent reduction in the risk of disease progression or death. The combination regimen was generally well tolerated and presented a manageable safety profile.